Bernard D. King
Chief Executive Officer
Small Molecule for Atopic Dermatitis
THESAN PHARMACEUTICAL INC.
United States of America
Dr. Bernard King has more than 25 years’ experience managing business and development operations in the pharmaceutical, medical device, biotechnology and CRO industries. In particular, he has directed, or been directly involved in, development programs for more than 100 pharmaceutical, medical device and biologics products. He has also served in several operational roles on behalf of clients including, President and CEO, Head of Development, VP Clinical Affairs, and VP Regulatory Affairs. Prior to starting Macnas, Dr. King was president and CEO of Predict, Inc. (bioinformatics), VP and General Manager for San Diego Operations for PAREXEL & Head of PAREXEL’s Emerging Growth Opportunities Group; EVP for Biological Sciences and Medical Affairs at Trega Biosciences; President of Segenix, a spinout of Advanced Tissue Sciences, where Dr. King had previously headed Research and Development; VP Worldwide Medical and Regulatory Affairs for ConvaTec, a BristolMyers Squibb subsidiary; and, Director of Clinical Investigation at SmithKline. Dr. King graduated cum laude from the University of Notre Dame, majoring in English and Pre-professional Studies, and received his MD from the Ohio State University College of Medicine. Following completion of residency training in Medicine and Pathology at Ohio State and his Cardiology fellowship training at the Mt. Sinai Medical Center in New York, he was an Assistant Professor in Medicine (Cardiology) and Physiology at New York Medical College. He is board certified in Cardiology and Internal Medicine. He received his MBA from the Wharton School of the University of Pennsylvania. Dr. King has authored a book on development entitled, Get It Right The First Time! Pharmaceutical Product Development: Intelligent Solutions for Challenging Issues.
Biopharmaceutical company, novel therapeutics for disorders of the skin